Massachusetts Institute of Technology, Lincoln Laboratory, Lexington, MA 02420, USA.
Med Hypotheses. 2021 Dec;157:110700. doi: 10.1016/j.mehy.2021.110700. Epub 2021 Oct 13.
A subset of COVID-19 patients is experiencing secondary immune thrombocytopenia, also called immune thrombocytopenic purpura (ITP) or secondary hemophagocytic lymphohistiocytosis (HLH). The pathogenesis of SARS-CoV-2 associated thrombocytopenia is unknown. Very rare cases of vaccine induced prothrombotic immune thrombocytopenia (VIPIT) are occurring associated with COVID-19 vaccines. COVID-19 VIPIT is associated with autoantibodies targeting platelet factor 4 (PF4) for COVID-19 adenovirus vaccines. Herein, four models for hemophagocytic histocytes contributions to the etiology of thrombocytopenia associated with SARS-CoV-2 are proposed. One of the models proposes potential involvement of hemophagocytic histocytes targeting platelets bound by autoantibodies consistent with observed PF4 autoantibodies in COVID-19 VIPIT.
一小部分 COVID-19 患者出现继发性免疫性血小板减少症,也称为免疫性血小板减少性紫癜(ITP)或继发性噬血细胞性淋巴组织细胞增生症(HLH)。SARS-CoV-2 相关血小板减少症的发病机制尚不清楚。与 COVID-19 疫苗相关的非常罕见的疫苗诱导性促血栓形成免疫性血小板减少症(VIPIT)病例正在发生。COVID-19 VIPIT 与针对血小板因子 4(PF4)的针对 COVID-19 腺病毒疫苗的自身抗体相关。在此,提出了与 SARS-CoV-2 相关血小板减少症相关的噬血细胞组织细胞对病因学的四种可能的贡献模型。其中一个模型提出了噬血细胞组织细胞潜在参与的可能性,这些噬血细胞组织细胞针对与自身抗体结合的血小板,这与 COVID-19 VIPIT 中观察到的 PF4 自身抗体一致。